New cancer drug combo enters human trials for Tough-to-Treat tumors
Disease control
Recruiting now
This study is testing a new drug called ADG126 in combination with an existing immunotherapy (pembrolizumab) for people with advanced solid tumors that have spread. The main goals are to find the safest and most effective dose and to see if the combination can help control the ca…
Phase: PHASE1, PHASE2 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC